Synergy Pharma (SGYP) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. CVS
7. SPY
8. UNH
9. SBUX
10. AXP

Go back to Synergy Pharma (SGYP) Misses Q1 EPS by 1c

Synergy Pharmaceuticals Reports 2015 First Quarter Results and Business Update

May 11, 2015 4:15 PM EDT

Completed enrollment in both phase 3 clinical trials with plecanatide for chronic idiopathic constipation (CIC) - pivotal data readouts expected in 2Q and 3Q 2015 Continued to advance plecanatide phase 3 program for irritable bowel syndrome with constipation (IBS-C) first pivotal data readout expected in 4Q 2015 Company on-track for first NDA filing with plecanatide for CIC in 4Q 2015

NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development of novel treatments for gastrointestinal diseases and disorders,... More